This whitepaper explores the financial impact of the benefit redesign and trends on EGWPs, estimating potential net premium increases for selected benefit designs.

This paper introduces national average drug acquisition costs (NADAC) and describes the opportunities and limitations of using NADAC as a basis for pharmacy pricing.

There is growing evidence supporting the power of cognitive diversity to further support and expand traditional diversity initiatives.

How would Medicare Part D spending be affected if the catastrophic phase included a drug discount program with no beneficiary cost sharing or reduced federal reinsurance?

With pharmacy costs continuing to rise, plan sponsors will realize increased value by assessing pharmacy benefit manager contract performances.